July 21, 2022
Daiichi Sankyo said on July 20 that a US federal court has entered judgement on a jury verdict made in April, ruling that the company willfully infringed a patent owned by Seagen with its cancer drug Enhertu (trastuzumab deruxtecan). The...read more